Sanofi inks marketing pact with Emcure for cancer drugs
Aug 06 2014 , New Delhi
As per the agreement, Sanofi will continue to own its oncology range comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec, while Emcure will market and distribute these brands through its specialty unit, Sanofi India said in a filing to the BSE.
"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," Sanofi Vice-President-South Asia and Sanofi India Managing Director Shailesh Ayyangar said.
Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing oncology business, he added.
Emcure Pharmaceuticals Managing Director Satish Mehta said: "We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions."
Sanofi India Ltd shares were trading at Rs 2,886 a piece on the BSE in afternoon trade, up 0.27% from its previous close.